The creators of the first and only nutritional protocol, that has been tested through an IRB-approved human clinical trial, are gearing up to begin R&D operations in Helsinki. The company is looking to validate their product locally as the first step to European expansion. Preliminary studies show promise: Rejuvalyte would offer relief to the treatment of Metabolic Syndrome, a significant health challenge, while answering to a currently unmet need in the market.
Opportunities in Helsinki were introduced to Rejuvalyte in 2016 by Helsinki Business Hub and their partner organization PrEver Consulting. After exploring local business ecosystems responsible for innovation, entrepreneurship and company set-up in the Nordic region, a decision was made: Rejuvalyte was determined to take advantage of the excellent local opportunities available and establish a base for European operations in Helsinki.
Convinced by Helsinki’s supportive business environment
“The key advantage is the business-friendly environment of Helsinki and its physical proximity to other European capitals. Also, the business loans and R&D grants provided by the funding arm of the Finnish government are encouraging to international companies looking to grow in the European market”, says Dr Farid Khan, CEO of Rejuvalyte.
The California-based company offers clinically proven safe and effective nutritional cleansing and detoxification programmes. Rejuvalyte’s innovative protocol is designed to support and enhance the body’s own mechanisms for managing toxins and metabolic waste by providing proper nourishment, reducing the toxic load, and providing internal rest. In recent years the company has grown its distribution to hub locations in South-America, Asia and Europe, more specifically Helsinki.
“Helsinki Business Hub made it easy for us to set up a subsidiary in Finland within a short time-frame. They recommended various vendors and facilitated the process of engaging them. They also provide great networking opportunities, which were often the source of meaningful business connections”, Dr Khan explains.
Finland first, Europe second
After establishing in Helsinki and exploring local business opportunities, first on the agenda was conducting a market feasibility study to map out needs and demands of Finnish Healthcare. The results of the study are encouraging to say the least.
“The study, completed by a Healthcare Consulting Group, proved that there is an unmet need in Finland in regard to Metabolic Syndrome and its medical management. Rejuvalyte would provide a solution to a significant health problem and also yield healthcare cost savings in the process. We are now preparing to conduct an R&D project with support from TEKES that would engage key players in the public and private sectors of healthcare to objectively explore the benefits that Rejuvalyte has to offer,” says Dr Khan.
So far two hires have been made to Rejuvalyte Finland, including Country Director. Once synergies and collaboration with local agencies have been strengthened, the goal is to set up a clinical R&D centre in Finland to leverage the Health Sciences and Clinical Research advances made in this part of the EU and accelerate market operations in Europe with Finland as a base in the EU region.